Frequency factor Her-2/neu overexpression in patients with breast cancer;Frecuencia de sobrexpresión del factor Her-2/neu en pacientes con cáncer de mama

Ginecologia y Obstetricia de Mexico

Volumn 82, Issue 6, 2014, Pages 369-376

  Mamani Cancino, Alex Daniel ^a   Veloz Martínez, María Guadalupe ^a   Casasola Busteros, Ivonne ^a   Moctezuma Meza, Christian ^a   García Cebada, Juan Manuel ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Breast cancer; Hormone receptor; Overexpression of Her 2 neu factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LONGITUDINAL STUDIES; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84902317897     PISSN: 03009041     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Akivama T. Sudo C. Ogawara H. Toyoshima K. Yamamoto T. The product of the human c-erB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232(4758): 1644-1650.
2. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Lilis L, et al. Expression of ras p21, p53 and c-erbB-2in advanced breast cancer and response to first line hormonal therapy. Brt Cancer 1995; 72: 1259-1266.
3. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of Her-2/neu gene amplification human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
4. Borg A, Baldetorp B, Femo M, Killander D, Olsson II, Ryden S, Sigurdsson H. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994; 81: 137-144.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235(4785): 177-182.
6. Slamon IXI, Godolphin W, Jones LA, Ilolt JA, Wong SG, Keith WJ, Levin WJ, Stuart SG, Udove J, Ulldrich A, et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244(4905): 707-12.
7. Egervari K, Szoliosi N, Nemos Z. Immunohistochemical antibodies in brest cancer Her-2/neu diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study. Tumour Biol 2008; 29: 18-27.
8. Jones A. Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why? Royal Free Hospital Clinical Oncology. London. UK, 2003 European Society for Medical Oncology.
9. Persons DI, Bui MM, Lowery MC, Mark III, Yung JF, et al. Fluorescence in situ hybridization for detection of Her-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci 2000; 30: 41-48.
10. Berns EM, Foekens JA, Staveren IL, Van Putten WL, De Koning HY, Portengen II, Klijn JG. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995; 159: 1-18.
11. Berry DA, Muss HB, Thor AD, et al. Her-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive. Node positive breast cancer. Clin Oncol 2000; 18: 3471-3479.
12. De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, et al. Twentyyear results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen eflicaccy in early breast cancer. Clin Cancer Res 2003; 9: 1039-46.
13. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, et al. Comparison of Her-2/neu status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. Clin Oncol 2005; 23: 4287-4297.
14. Borg A, Tandon AK, Sigurdsson H, Clark GM, Femo M, Fuqua SAW, et al. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 4332-4337.
15. Carlomagno C, Perrone F, Gallo C, De Laurentis M, Lauria R, et al. Her-2/neu overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Clin Oncol 1996; 10: 2702-2708.